Aequus Pharmaceuticals Inc. (TSXV:AQS)
Canada · Delayed Price · Currency is CAD 0.0050
0.00 (0.00%)
Apr 25, 2025, 9:30 AM EST
Aequus Pharmaceuticals Balance Sheet
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 0.01 | 0.05 | 0.17 | 0.25 | 2.39 | 1.72 |
Short-Term Investments | - | - | 0.04 | 0.04 | 0.04 | - |
Cash & Short-Term Investments | 0.01 | 0.05 | 0.22 | 0.29 | 2.44 | 1.72 |
Cash Growth | -80.27% | -76.64% | -27.02% | -87.91% | 41.75% | 254.77% |
Accounts Receivable | 0.17 | 0.06 | 0.03 | 0.31 | 0.94 | 0.78 |
Inventory | 0 | 0.04 | 0.12 | 0.09 | 0.14 | 0.12 |
Other Current Assets | 0.01 | 0.14 | 0.07 | 0.2 | 0.08 | 0.15 |
Total Current Assets | 0.2 | 0.28 | 0.44 | 0.9 | 3.59 | 2.77 |
Net Property, Plant & Equipment | - | 0.52 | 0.65 | 0.79 | 0.24 | 0.37 |
Long-Term Investments | - | - | - | - | 0.51 | - |
Total Assets | 0.2 | 0.8 | 1.09 | 1.69 | 4.35 | 3.13 |
Liabilities
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Accounts Payable | 1.02 | 0.54 | 0.27 | 0.09 | 0.16 | 0.16 |
Accrued Expenses | 0.04 | 0.1 | 0.04 | 0.2 | 0.22 | 0.08 |
Short-Term Debt | 6.03 | 6.03 | 4.37 | 2 | - | - |
Current Portion of Long-Term Debt | - | - | - | - | 1.93 | 1.95 |
Current Portion of Leases | - | 0.12 | 0.11 | 0.09 | 0.15 | 0.15 |
Total Current Liabilities | 7.09 | 6.8 | 4.8 | 2.38 | 2.46 | 0.38 |
Long-Term Debt | - | - | - | - | 0.03 | 0.02 |
Long-Term Leases | - | 0.46 | 0.58 | 0.69 | 0.08 | 0.2 |
Total Long-Term Liabilities | - | 0.46 | 0.58 | 0.69 | 0.1 | 0.22 |
Total Liabilities | 7.09 | 7.26 | 5.38 | 3.07 | 2.56 | 2.56 |
Shareholders' Equity
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Common Stock | 23.99 | 23.99 | 23.99 | 23.99 | 23.99 | 21.17 |
Additional Paid-in Capital | 4.42 | 4.42 | 4.4 | 4.35 | 4.31 | 4.1 |
Retained Earnings | -35.3 | -34.86 | -32.68 | -29.72 | -26.51 | -24.7 |
Shareholders' Equity | -6.89 | -6.45 | -4.29 | -1.38 | 1.79 | 0.57 |
Total Liabilities & Equity | 0.2 | 0.8 | 1.09 | 1.69 | 4.35 | 3.13 |
Additional Metrics
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Total Debt | 6.03 | 6.61 | 5.06 | 2.78 | 2.18 | 2.32 |
Net Cash (Debt) | -6.02 | -6.56 | -4.85 | -2.49 | 0.26 | -0.6 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -0.04 | -0.05 | -0.04 | -0.02 | - | -0.01 |
Book Value | -6.89 | -6.45 | -4.29 | -1.38 | 1.79 | 0.57 |
Book Value Per Share | -0.05 | -0.05 | -0.03 | -0.01 | - | 0.01 |
Tangible Book Value | -6.89 | -6.45 | -4.29 | -1.38 | 1.79 | 0.57 |
Tangible Book Value Per Share | -0.05 | -0.05 | -0.03 | -0.01 | - | 0.01 |